Zobrazeno 1 - 10
of 1 227
pro vyhledávání: '"David Y, Graham"'
Autor:
David Y. Graham
Publikováno v:
Pharmacoepidemiology, Vol 3, Iss 1, Pp 82-93 (2024)
Helicobacter pylori is a class I carcinogen that infects more than 100 million individuals in the United States. Antimicrobial therapy for H. pylori has typically been prescribed empirically rather than based on susceptibility testing. Until recently
Externí odkaz:
https://doaj.org/article/51b588d57ed24737a0cbb903e69ed31b
Autor:
David Y. Graham, Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M. Scott Harris, Shuhong Zhao, Ira N. Kalfus
Publikováno v:
Antibiotics, Vol 13, Iss 8, p 694 (2024)
This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting Mycobacterium avium subspecies paratuberculosis (MAP), long considered a putative cause, would favorably affect Cro
Externí odkaz:
https://doaj.org/article/e2493f4da86e452f9ac5eb4e6ef7ff2d
Autor:
David Y. Graham
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
The recent availability of susceptibility testing for Helicobacter pylori infections in the United Sates has resulted in paradigm shifts in the diagnosis, therapy, and follow-up of H. pylori infections. Here, we reviewed the English literature concer
Externí odkaz:
https://doaj.org/article/eb5b60a46ea143d496aa9d1f5b528f46
Autor:
Yi Hu, Xin Xu, Xiao-Shun Liu, Cong He, Yao-Bin Ouyang, Nian-Shuang Li, Chuan Xie, Chao Peng, Zhen-Hua Zhu, Yong Xie, Xu Shu, Yin Zhu, David Y. Graham, Nong-Hua Lu
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
Background and aimWe previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for Helicobacter pylori (H. pylori) eradication. We aimed to explore the efficacy of VA dual therapy for 14 days
Externí odkaz:
https://doaj.org/article/7d7d656c4e1c431e847bca9220cb56f6
Autor:
Ritwick Agrawal, Nadim J. Ajami, Sonal Malhotra, Liang Chen, Donna L. White, Amir Sharafkhaneh, Kristi L. Hoffman, David Y. Graham, Hashem B. El-Serag, Joseph F. Petrosino, Li Jiao
Publikováno v:
Clocks & Sleep, Vol 3, Iss 3, Pp 387-397 (2021)
We examined the association between the colonic adherent microbiota and nocturnal sleep duration in humans. In a cross-sectional study, 63 polyp-free adults underwent a colonoscopy and donated 206 mucosal biopsies. The gut microbiota was profiled usi
Externí odkaz:
https://doaj.org/article/35647dbb90224b62bacc0af1e4fa3c21
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
The diagnosis and therapy of Helicobacter pylori infection have undergone major changes based on the use the principles of antimicrobial stewardship and increased availability of susceptibility profiling. H. pylori gastritis now recognized as an infe
Externí odkaz:
https://doaj.org/article/c9b02b80bb14465e886834a5b7d7528f
Autor:
David Y. Graham
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Externí odkaz:
https://doaj.org/article/ad35d34d53aa4a0db4cb80d01f229922
Publikováno v:
The Lancet Gastroenterology & Hepatology. 8:553-564
Autor:
Faith D. Ihekweazu, Tatiana Y. Fofanova, Karen Queliza, Dorottya Nagy-Szakal, Christopher J. Stewart, Melinda A. Engevik, Kristina G. Hulten, Nina Tatevian, David Y. Graham, James Versalovic, Joseph F. Petrosino, Richard Kellermayer
Publikováno v:
Gut Microbes, Vol 10, Iss 4, Pp 504-520 (2019)
Background and aims Bacteriotherapy aimed at addressing dysbiosis may be therapeutic for Inflammatory Bowel Diseases (IBDs). We sought to determine if defined Bacteroides-based bacteriotherapy could be an effective and consistent alternative to fecal
Externí odkaz:
https://doaj.org/article/3befe0b806fb4a3fbb70bcee18830637
Autor:
David Y. Graham
Publikováno v:
Digestive Diseases and Sciences. 68:1691-1697